Co-Authors
This is a "connection" page, showing publications co-authored by Jonathan Wren and James Battiste.
Connection Strength
0.284
-
OKN-007 Increases temozolomide (TMZ) Sensitivity and Suppresses TMZ-Resistant Glioblastoma (GBM) Tumor Growth. Transl Oncol. 2019 Feb; 12(2):320-335.
Score: 0.163
-
Optimized monoclonal antibody treatment against ELTD1 for GBM in a G55 xenograft mouse model. J Cell Mol Med. 2020 01; 24(2):1738-1749.
Score: 0.044
-
Targeting ELTD1, an angiogenesis marker for glioblastoma (GBM), also affects VEGFR2: molecular-targeted MRI assessment. Am J Nucl Med Mol Imaging. 2019; 9(1):93-109.
Score: 0.041
-
ELTD1, an effective anti-angiogenic target for gliomas: preclinical assessment in mouse GL261 and human G55 xenograft glioma models. Neuro Oncol. 2017 02 01; 19(2):175-185.
Score: 0.036